Aerovate Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
AVTE on Nasdaq
Industry
Pharmaceutical Preparations
Location
930 Winter Street, Suite M 500, Waltham, MA

Insiders trading volume in the past year

Aerovate Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Ra Capital Management, L.P. Director, 10%+ Owner $198M Jun 17, 2024
Sofinnova Venture Partners X, L.P. 10%+ Owner $73.3M Jul 2, 2021
David S. Grayzel Director $50.9M -$334K -0.65% Jun 5, 2024
Atlas Venture Fund XII, L.P. 10%+ Owner $45.4M Jul 15, 2022
Cormorant Asset Management, LP Former 10% Owner $39.6M Jul 2, 2021
Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director $5.62M -$1.01M -15.2% May 16, 2024
Hunter Gillies Chief Medical Officer $1.5M -$1.46M -49.3% Jun 13, 2024
Marinus Verwijs Chief Technical Officer $1.13M -$610K -35.1% Jun 14, 2024
Timothy Pigot Chief Commercial Officer $923K Jan 22, 2024
George A. Eldridge Officer Title: Chief Financial Officer and Treasurer $597K -$1.72M -74.2% Jun 14, 2024
Ralph Niven Chief Scientific Officer $591K -$450K -43.2% Feb 5, 2024
Allison Dorval Director $205K Jun 5, 2024
Habib J. Dable Director $205K Jun 5, 2024
Donald J. Santel Director $205K Jun 5, 2024
Mark T. Iwicki Director $205K Jun 5, 2024
Joshua Resnick Director $205K Jun 5, 2024
Maha Katabi Director, 10%+ Owner $205K Jun 5, 2024
Benjamin T. Dake Officer Title: President, Chief Operating Officer and Secretary $24.8K -$2.16M -98.9% Jul 31, 2024

Recent Insider Transactions by Companies or Individuals for Aerovate Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.